- Male or female subjects aged 18 years or older at the time of enrollment.
- All female and male subjects who are biologically capable of having children must
agree and commit to the use of a reliable method of birth control from the signing of
the informed consent form (ICF) until 3 months after the last dose of investigational
product.
- Documented vaccination with 1 or more doses of 23vPS at least 6 months before study
enrollment.
- CD4+ T-cell count >= 200 cells/µ, obtained on the most recent 2 occasions within 6
months before the first investigational product vaccination.
- HIV-infected subjects with viral load occasions within 6 months before the first investigational product vaccination.
- Subject is receiving a stable dose of HAART for at least 6 weeks prior to the first
investigational product vaccination, or not currently receiving antiretroviral
therapy.
- Subject is expected to be available for the entire study period (approximately 18
months) and can be contacted by telephone.
- Subject must be able to complete an electronic diary (e-diary) and complete all
relevant study procedures during study participation.
- Subject is deemed to be eligible for the study on the basis of medical history,
physical examination, and clinical judgment. (Note: Subjects with preexisting stable
disease, defined as disease not requiring significant change in therapy or
hospitalization for worsening disease 6 weeks before investigational product
vaccination, are eligible.)
- Subjects with active AIDS related illness, including opportunistic infections or
malignancy.
- Evidence of current illicit substance and/or alcohol abuse, that in the investigator's
opinion, precludes the subject from participating in the study or interferes with the
evaluation of the study objectives..
- Receipt of any licensed or experimental pneumococcal conjugate vaccine prior to
enrollment.
- Contraindication to vaccination with pneumococcal conjugate vaccine.
- Previous anaphylactic reaction to any vaccine or vaccine-related component.
- History of culture-proven invasive disease caused by Streptococcus pneumoniae within
the last year.
- Current anticoagulant therapy or a history of bleeding diathesis or any condition
associated with prolonged bleeding time that would contraindicate intramuscular
injection. (Note: Use of antiplatelet drugs, such as aspirin and clopidogrel, is
permitted.)
- Pregnant or breastfeeding women, as defined by history or positive human chorionic
gonadotropin (hCG) urine test. All women of childbearing potential must have a urine
pregnancy test.
- History of active hepatitis with elevation in pretreatment aspartate aminotransferase
(AST) or alanine aminotransferase (ALT) values >5 times the upper limit of normal
within the last 6 months.
- Serious chronic disorder or any other disorder that, in the investigator's opinion,
precludes the subject from participating in the study or interferes with the
evaluation of the study objectives. (Note: Serious chronic disorders include
metastatic malignancy, severe chronic obstructive pulmonary disease requiring
supplemental oxygen, end-stage renal disease with or without dialysis, and clinically
unstable cardiac disease).
- Any major illness/condition that, in the investigator's judgment, will substantially
increase the risk associated with the subject's participation in and completion of,
the study, or could preclude the evaluation of the subject's response.
- History of splenectomy.
- Receipt of any blood products, including immunoglobulin, within 42 days before
investigational product vaccination until the last blood draw for the study
(approximately 13 months after the first investigational product vaccination).
- Evidence of dementia or other severe cognitive impairment.
- Subject who is, in the opinion of the investigator, unable to receive a vaccination in
the deltoid muscle of either arm because of insufficient muscle mass.
- Participation in another study using investigational product from 28 days before study
enrollment until the blood draw at visit 6. Between the blood draw at visit 6 and the
6 month follow-up telephone call (visit 7), use of investigational product must be
discussed with the Medical Monitor. (Note: Participation in purely observational
studies is acceptable.)
- Residence in a nursing home, long-term care facility, or other institution or
requirement of semi-skilled nursing care. An ambulatory resident of a retirement home
or village is eligible for the trial.
- Subject who is a direct relative (child, grandchild, parent, or grandparent) of study
personnel, or who is study personnel.
Temporary Delay Criteria:
- Current febrile illness (oral temperature of =38.0°C [100.4°F]) or other acute illness
within 48 hours before study vaccine administration.
- Currently receiving antibiotic therapy, or has completed a course of antibiotic
therapy within 10 days before study vaccine administration.
- Receipt of novel influenza A (H1N1) vaccine within 14 days before investigational
product vaccination (seasonal influenza vaccine can be given at any time at the
discretion of the investigator).